Premium
Systematic review and network meta‐analysis: Comparative effectiveness of therapies for second‐line Helicobacter pylori eradication
Author(s) -
Yeo Yee Hui,
Hsu ChiaChen,
Lee ChiaoChin,
Ho Hsiu J,
Lin JawTown,
Wu MingShiang,
Liou JyhMing,
Wu ChunYing
Publication year - 2019
Publication title -
journal of gastroenterology and hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.214
H-Index - 130
eISSN - 1440-1746
pISSN - 0815-9319
DOI - 10.1111/jgh.14462
Subject(s) - medicine , regimen , helicobacter pylori , meta analysis , adverse effect , odds ratio , randomized controlled trial , surgery
Background and Aim The eradication rate of Helicobacter pylori ( H. pylori ) has been declining over the past decades. A rescue plan is needed for increasing populations with treatment failure. However, the optimum second‐line eradication regimen remains inconclusive. We conducted a network meta‐analysis to assess the comparative effectiveness of second‐line H. pylori eradication therapies and determine the optimum regimen. Methods We searched electronic databases from January 2005 to February 2018 for randomized controlled trials assessing the effectiveness of second‐line regimens in patients with persistent H. pylori infection after first‐line treatment. Bayesian network meta‐analysis was performed to combine the direct and indirect evidence and to investigate the rank order of second‐line therapies. We also appraised the quality of evidence using Grading of Recommendations Assessment, Development, and Evaluation guidance. Results Twenty‐six trials with 3628 participants who received second‐line eradication therapy were identified. All regimens showed pooled eradication rates < 90%. Compared with 7‐day triple therapy, quinolone‐based (odds ratio [OR] 4.29, 95% credible interval [CrI] 1.67–12.12, surface under the cumulative ranking [SUCRA] 0.95), non‐quinolone‐based bismuth‐containing quadruple therapies for 10 days or more (OR 2.25, 95% CrI 1.10–4.62, SUCRA 0.78), and sequential therapy (OR 2.91, 95% CrI 1.16–7.65, SUCRA 0.66) showed significantly higher effectiveness. Overall, regimens with longer duration demonstrated higher eradication rates but higher rates of adverse events. More adverse events were reported in those patients treated with concomitant therapy. Conclusions Quinolone‐based bismuth‐containing quadruple therapies for 10 days or more are the optimum second‐line regimens for H. pylori eradication.